asc41
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 16, 2020 (NCT04527250)
Timeline
Indications
Mechanism of action
THRB agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05462353 | Phase 2 | Sep 30, 2022 | Gannex Pharma Co., Ltd. |
| NCT05118360 | Phase 2 | Dec 2, 2021 | Gannex Pharma Co., Ltd. |
| NCT04845646 | Phase 1 | Mar 16, 2021 | Gannex Pharma Co., Ltd. |
| NCT04692025 | Phase 1 | Dec 27, 2020 | Central South University, Gannex Pharma Co., Ltd. |
| NCT04686994 | Phase 1 | Dec 22, 2020 | Central South University, Gannex Pharma Co., Ltd. |
| NCT04527250 | Phase 1 | Sep 16, 2020 | Ascletis Pharmaceuticals Co., Ltd., Central South University |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gannex Pharma Co., Ltd. | For profit | 5 | 5 | 2 | 2020 |
| Central South University | Academic/Hospital | 3 | 0 | 1 | 2020 |
| Ascletis Pharmaceuticals Co., Ltd. | For profit | 1 | 1 | 1 | 2020 |
3 organizations
Page 1 / 1